Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $13.79.

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Truist Financial reaffirmed a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday. Finally, Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th.

Marinus Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ MRNS opened at $1.33 on Friday. Marinus Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $11.26. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93. The company has a market capitalization of $73.06 million, a price-to-earnings ratio of -0.50 and a beta of 1.11. The business has a 50-day moving average of $1.42 and a two-hundred day moving average of $6.70.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, meeting the consensus estimate of ($0.68). The firm had revenue of $7.68 million during the quarter, compared to the consensus estimate of $8.61 million. Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. On average, analysts forecast that Marinus Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Several large investors have recently modified their holdings of MRNS. China Universal Asset Management Co. Ltd. grew its stake in shares of Marinus Pharmaceuticals by 383.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 5,003 shares in the last quarter. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals in the fourth quarter worth about $134,000. Sherbrooke Park Advisers LLC acquired a new position in Marinus Pharmaceuticals in the third quarter worth about $141,000. Acuta Capital Partners LLC acquired a new position in Marinus Pharmaceuticals in the third quarter worth about $157,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Marinus Pharmaceuticals in the first quarter worth about $384,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.